BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24369899)

  • 1. c-Src activation through a TrkA and c-Src interaction is essential for cell proliferation and hematological malignancies.
    Kim MS; Kim GM; Choi YJ; Kim HJ; Kim YJ; Jin W
    Biochem Biophys Res Commun; 2013 Nov; 441(2):431-7. PubMed ID: 24369899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1.
    Kim MS; Kim GM; Choi YJ; Kim HJ; Kim YJ; Jin W
    Mol Cells; 2013 Aug; 36(2):177-84. PubMed ID: 23832765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
    Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells.
    Brizzi MF; Rosso A; Dentelli P; Ferrero D; Lanfrancone L; Pegoraro L
    Exp Hematol; 1998 Dec; 26(13):1229-39. PubMed ID: 9845379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
    Kharas MG; Fruman DA
    Cancer Res; 2005 Mar; 65(6):2047-53. PubMed ID: 15781610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway.
    Basile JR; Afkhami T; Gutkind JS
    Mol Cell Biol; 2005 Aug; 25(16):6889-98. PubMed ID: 16055703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
    Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
    J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
    Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
    Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia.
    Hans CP; Finn WG; Singleton TP; Schnitzer B; Ross CW
    Am J Clin Pathol; 2002 Feb; 117(2):301-5. PubMed ID: 11863227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
    Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.